# Understanding the New Medicare Prescription Payment Plan

What you need to know for 2025

## What Medicare Part D changes mean for patients prescribed CREXONT<sup>®</sup> and ONGENTYS<sup>®</sup>

For Medicare Part D patients considering or currently taking CREXONT or ONGENTYS, this change means their out-of-pocket costs will go away or be capped once they reach the \$2,000 maximum\*.

Patients will continue to pay their deductible, along with copays or coinsurance during the initial coverage phase. However, after reaching the **\$2,000 out-of-pocket limit, they will no longer incur any out-of-pocket costs for these medications for the remainder of the year.** 

This provides greater predictability in managing prescription drug expenses.





https://ongentyshcp.com/

©2024 Amneal Specialty, a division of Amneal Pharmaceuticals LLC. All rights reserved. CREXONT® is a trademark of Amneal Pharmaceuticals. The information contained herein are intended for use by U.S. residents only. Amneal Pharmaceuticals' rights to promote, offer for sale, and sell ONGENTYS are limited to the U.S. ONGENTYS® is a registered trademark of BIAL - Portela & C<sup>a</sup>., S.A. PP-ADP-NP-US-0015 10/24 Under license from IBC II







#### What changes are coming for Medicare prescription drug costs?

Here are two important changes you should know about the out of pocket prescription drug costs for patients enrolled in the Medicare Part D Prescription Program:

### Medicare Part D patients out-of-pocket costs will be capped at \$2,000 in 2025\*

2024 prescription medication guidelines limited the maximum amount of out of pocket prescription drug costs for patients.

**2024 maximum** out of pocket prescription drug costs

> \$3,300-\$3,800 for all covered Part D medications

**2025 maximum** out of pocket prescription drug costs

**\$2,000** for all covered Part D medications

# For 2025 and beyond: The Medicare Prescription Payment Plan can make costs more predictable\*\*

The payment plan option allows enrolled patients to pay prescription drug costs as fixed monthly payments to their Medicare Part D plan. **Open enrollment begins October 15, 2024. Patients must enroll to participate in this program. This new option is effective January 1, 2025.** 

#### Patients who enroll in the payment plan

- Patients enrolled before January 1, 2025, could have MAXIMUM payments of ~\$166.67 per month (12 payments) for all of their covered pharmacy medications, for a yearly total of \$2,000\* directly made to their Medicare Part D plan.
- Enrolled patients have <u>NO</u> additional pharmacy co-pays.

\* Includes Medicare Part D (PDPs), Medicare Part C with prescription drug coverage (MA-PDs), and those enrolled in Medicare Savings Programs and the Medicare Part D Extra Help Program. \*\*For more information, visit Centers for Medicare & Medicaid Services (https://www.cms.gov/)

©2024 Amneal Specialty, a division of Amneal Pharmaceuticals LLC. All rights reserved. CREXONT® is a trademark of Amneal Pharmaceuticals. The information contained herein are intended for use by U.S. residents only. Amneal Pharmaceuticals' rights to promote, offer for sale, and sell ONGENTYS are limited to the U.S. ONGENTYS® is a registered trademark of BIAL - Portela & C<sup>a</sup>., S.A. PP-ADP-NP-US-0015 10/24 Under license from Coloration

